EVAX (Evaxion AS) Research & Development: $10.12 Mil (TTM As of Mar. 2026)


EVAX Evaxion AS EVAX
22 GF Score
Price $3.23
! 2 Warning Signs
View Full Analysis

What is Evaxion AS Research & Development?

Evaxion AS EVAX -1.59% 22 Research & Development is $10.12 Mil as of Mar. 2026. GuruFocus rates EVAX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Evaxion AS's Research & Development for the three months ended in Mar. 2026 was $2.30 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $10.12 Mil.

Evaxion AS  (NAS:EVAX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Evaxion AS Research & Development Related Terms

Evaxion AS Research & Development Historical Data

* Premium members only.

The historical data trend for Evaxion AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evaxion AS Research & Development Chart

Evaxion AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 19.58 17.06 11.92 10.46 9.98

Evaxion AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.16 2.17 3.09 2.56 2.30
EVAX
22GF Score
Evaxion AS EVAX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evaxion AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $10.12 Mil mean?
Evaxion AS (EVAX) has a Research & Development of $10.12 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Evaxion AS and its competitors.
Is Evaxion AS's Research & Development too high?
Evaxion AS's current Research & Development is $10.12 Mil. Overall, Evaxion AS has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's Research & Development compare to DARE and LITS?
Evaxion AS's Research & Development of $10.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Evaxion AS and its competitors. Evaxion AS's current Research & Development is $10.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Evaxion AS (EVAX) has a current Research & Development of $10.12 Mil. The current Research & Development is $10.12 Mil. Evaxion AS's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Evaxion AS (EVAX), the current Research & Development is $10.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evaxion AS Business Description

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
22GF Score

Get the complete analysis for EVAX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.23
Price